RHCPA
Ramsay Health Care Limited
🇦🇺 ASX
🩺 HEALTH CARE
🍃 HIGH ESG SCORE
🌳 ENVIRONMENTAL
🕊️ SOCIALLY AWARE
💰 HIGH DIVIDEND
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
-0.67%
Annual Growth
5 years average annual growth
💰
6.39%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Ramsay Health Care Ltd. engages in the healthcare services and the operation of hospitals and day surgery facilities. The company is headquartered in Sydney, New South Wales and currently employs 90,000 full-time employees. The Company’s segments include Asia Pacific, UK, France and Nordics. Its businesses include Ramsay Australia, Ramsay Sante, Ramsay UK, and Elysium Healthcare. Ramsay Australia has over 73 private hospitals and day surgery units in Australia. Ramsay Sante is a private care provider in Europe and operates 443 multidisciplinary hospitals and clinics and 130 primary care centers across five countries. Ramsay UK has a network of 34 acute hospitals and day procedure centers in England providing a comprehensive range of clinical specialties to private and self-insured patients. Elysium Healthcare is an independent sector provider of specialist health and care services. Its four core service streams are mental health, neurological, learning disabilities and children and education.
📈 Performance
Price History
+1.68%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
6.39%
💰 Annual Dividend Earnings Per $1,000 invested**
$63.91
💰 Most Recent Dividend Franked Percentage Estimate
100.00%
💰 Average Dividend Franked Percentage Estimate
100.00 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of RHCPA, your last dividend payment(s) would have been:
$ 441.21
on Mon Oct 21 2024
$ 442.85
on Mon Apr 22 2024
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2024
$6.63
100.00%
2023
$6.00
100.00%
2022
$3.78
100.00%
2021
$3.46
100.00%
2020
$3.81
100.00%
2019
$4.73
100.00%
2018
$4.84
100.00%
2017
$4.78
100.00%
2016
$5.04
100.00%
2015
$5.16
50.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🍃 Environmental, Social and Governance scores ℹ️
🌳
Environmental Score
99
A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution
⚖️
Governance Score
83
An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.
🤓 Advanced information
Technical Info
💰 Price*
$106.20
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RHCPA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in RHCPA
N/A
RHCPA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in RHCPA also invest in...
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.79%
📊 Share price
$68.90 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
12.84%
📊 Share price
$16.09 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.13%
📊 Share price
$137.57 AUD
⛳️ DIVERSIFIED
💸 FINANCIALS
🇦🇺 AUSTRALIA
COH
Cochlear Ltd. engages in the provision of implantable hearing solutions. The company is headquartered in Sydney, New South Wales and currently employs 5,000 full-time employees. The firm is engaged in development, manufacture and commercialization of implantable hearing solutions. Its segments include Cochlear implants, Services (sound processor upgrades and other) and Acoustics. The Company’s products and services portfolio include Cochlear implant portfolio, Acoustic solutions portfolio, and Recipient support tools. Its Cochlear Connected Care solutions include Cochlear Nucleus SmartNav System, Cochlear Custom Sound Pro Fitting Software, Cochlear Link, Cochlear Remote Assist, and Cochlear Remote Check solution for cochlear implants. Its Cochlear implant portfolio include Cochlear Nucleus System. Its Acoustic solutions portfolio include Cochlear Osia System, and Cochlear Baha System. Its Recipient support tools include Cochlear Nucleus, Baha and Osia Smart Apps and Cochlear CoPilot App.
🙌 Performance (5Yr p.a)
5.14%
📊 Share price
$292.27 AUD
🩺 HEALTH CARE
🕊️ SOCIALLY AWARE
CSL
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,398 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
🙌 Performance (5Yr p.a)
-0.04%
📊 Share price
$278.11 AUD
🧬 BIOTECHNOLOGY
🕊️ SOCIALLY AWARE
Want more shares? Try these...
Red Hill Minerals Ltd. engages in the exploration of base metals, gold and iron ores properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-02-14. The firm is focused on the West Pilbara Gold and Base Metal Project in Western Australia. The firm owns the Pannawonica Iron Ore Project and the Three Peaks Hard Rock Project and continues to seek opportunities to advance these projects. Its primary asset is Red Hill Iron Ore Joint Venture (RHIOJV). The firm has carried out studies for a quarrying concept based on porphyry rock outcrops at the Three Peaks site nearby to the Pannawonica Project. The Pannawonica Project is located north of the West Pilbara project area and comprises the Company’s 100% owned Redgate and Whitegate iron ore mining leases.
🙌 Performance (5Yr p.a)
375.22%
📊 Share price
$4.13 AUD
⛏️ MINING
Red Hawk Mining Ltd. engages in the development of mineral deposits. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-02-20. The firm is focused on developing its 100%-owned Blacksmith Iron Ore Project in the Pilbara region of Western Australia. The Blacksmith Project is located approximately 70km north-west of Tom Price and consists of mining lease M47/1451, which covers approximately 112 square kilometers (km2). The Blacksmith Project comprises seven shallow deposits: Ajax, Badger, Blackjack, Champion, Delta, Eagle and Paragon. In addition to the Blacksmith Project, the Company holds retention license R47/21 for the Anvil Project. Its Canegrass Project is located approximately 60 km south-east of Mt Magnet in the Murchison region of Western Australia. The tenement package comprises six granted exploration licenses, which are being explored for battery minerals, particularly vanadium and titanium.
🙌 Performance (5Yr p.a)
226.92%
📊 Share price
$0.80 AUD
⛏️ MINING
Argent Biopharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
🙌 Performance (5Yr p.a)
80.00%
📊 Share price
$0.15 AUD
📦 LOGISTICS
Ramsay Health Care Ltd. engages in the healthcare services and the operation of hospitals and day surgery facilities. The company is headquartered in Sydney, New South Wales and currently employs 90,000 full-time employees. The Company’s segments include Asia Pacific, UK, France and Nordics. Its businesses include Ramsay Australia, Ramsay Sante, Ramsay UK, and Elysium Healthcare. Ramsay Australia has over 73 private hospitals and day surgery units in Australia. Ramsay Sante is a private care provider in Europe and operates 443 multidisciplinary hospitals and clinics and 130 primary care centers across five countries. Ramsay UK has a network of 34 acute hospitals and day procedure centers in England providing a comprehensive range of clinical specialties to private and self-insured patients. Elysium Healthcare is an independent sector provider of specialist health and care services. Its four core service streams are mental health, neurological, learning disabilities and children and education.
🙌 Performance (5Yr p.a)
-10.60%
📊 Share price
$34.65 AUD
🩺 HEALTH CARE
🌳 ENVIRONMENTAL
🍃 HIGH ESG SCORE
🕊️ SOCIALLY AWARE
🕊️
Social Score
99
An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.